CompletedNCT00817648
Quetiapine or risperidone for acute schizophrenia in Chinese adults
About this title
A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia
Read the official source — NCT00817648Researchers compared Quetiapine and risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–65China
Understand this study
What did researchers investigate?
Researchers compared Quetiapine and risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Shanghai and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- Shanghai Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00817648
- Official title
Show the full official title
A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia
Get this study by email
Recruitment & locations
CompletedShanghai · Huzhou
Questions about this study
What did researchers investigate?
Researchers compared Quetiapine and risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Shanghai Mental Health Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine and risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolarity